William Carter - PetIQ Executive Counsel
| PETQDelisted Stock | USD 30.98 0.00 0.00% |
Executive
William Carter is Executive Counsel of PetIQ Inc
| Age | 54 |
| Phone | 208 939 8900 |
| Web | https://petiq.com |
William Carter Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Carter against PetIQ stock is an integral part of due diligence when investing in PetIQ. William Carter insider activity provides valuable insight into whether PetIQ is net buyers or sellers over its current business cycle. Note, PetIQ insiders must abide by specific rules, including filing SEC forms every time they buy or sell PetIQ'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Carter over two months ago Acquisition by William Carter of 5000 shares of PetIQ subject to Rule 16b-3 | ||
William Carter over two months ago Disposition of 1503 shares by William Carter of PetIQ at 30.48 subject to Rule 16b-3 |
PetIQ Management Efficiency
The company has return on total asset (ROA) of 0.0486 % which means that it generated a profit of $0.0486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0552 %, meaning that it created $0.0552 on every $100 dollars invested by stockholders. PetIQ's management efficiency ratios could be used to measure how well PetIQ manages its routine affairs as well as how well it operates its assets and liabilities.PetIQ Inc currently holds 468.3 M in liabilities with Debt to Equity (D/E) ratio of 1.81, which is about average as compared to similar companies. PetIQ Inc has a current ratio of 2.82, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PetIQ's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Esq III | Pacira BioSciences, | 50 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Volker Braun | Evotec SE ADR | N/A | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Sandeep Poddar | Dr Reddys Laboratories | N/A | |
| William Hartzel | Emergent Biosolutions | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Jiny MBA | Bausch Health Companies | 47 | |
| Christopher Young | Pacira BioSciences, | 52 | |
| Shawn Cross | Pacira BioSciences, | 56 | |
| Todd MBA | Supernus Pharmaceuticals | N/A | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Tien Chau | Regencell Bioscience Holdings | 54 | |
| Monika Conradt | Evotec SE ADR | N/A | |
| Haywood Miller | Emergent Biosolutions | N/A | |
| YatPui Au | Regencell Bioscience Holdings | 50 | |
| Cees Heiman | Bausch Health Companies | N/A | |
| Glenn David | Phibro Animal Health | 52 | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Arthur Shannon | Bausch Health Companies | N/A | |
Management Performance
| Return On Equity | 0.0552 | ||||
| Return On Asset | 0.0486 |
PetIQ Inc Leadership Team
Elected by the shareholders, the PetIQ's board of directors comprises two types of representatives: PetIQ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PetIQ. The board's role is to monitor PetIQ's management team and ensure that shareholders' interests are well served. PetIQ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PetIQ's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Herrman, Gen VP | ||
| Michael Smith, Executive Vice President Products | ||
| John Pearson, Executive Products | ||
| McCord Christensen, Chairman of the Board, CEO | ||
| Zvi Glasman, Chief Officer | ||
| William Carter, Executive Counsel | ||
| Jeff Caywood, Treasurer VP |
PetIQ Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PetIQ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0552 | ||||
| Return On Asset | 0.0486 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 1.3 B | ||||
| Shares Outstanding | 29.67 M | ||||
| Shares Owned By Insiders | 7.00 % | ||||
| Shares Owned By Institutions | 93.00 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | 130.31 X |
Pair Trading with PetIQ
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PetIQ position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PetIQ will appreciate offsetting losses from the drop in the long position's value.Moving together with PetIQ Stock
Moving against PetIQ Stock
| 0.59 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.58 | WUHN | Wuhan General Gr | PairCorr |
| 0.58 | CGC | Canopy Growth Corp | PairCorr |
| 0.57 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.57 | RGC | Regencell Bioscience | PairCorr |
The ability to find closely correlated positions to PetIQ could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PetIQ when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PetIQ - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PetIQ Inc to buy it.
The correlation of PetIQ is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PetIQ moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PetIQ Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PetIQ can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in PetIQ Stock
If you are still planning to invest in PetIQ Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PetIQ's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |